* The analysis found that high YAP1 expression is associated with worse overall survival (OS) and disease-free survival (DFS) for patients with digestive malignant tumors, particularly in gastric cancer, cholangiocarcinoma, and colorectal cancer.
* In pancreatic cancer specifically, patients with elevated YAP1 levels experienced significantly shorter survival times, suggesting YAP1 could serve as a valuable prognostic marker and possible therapeutic target for these types of cancer.